About this trial
Oral mucositis (OM) is a frequent, debilitating complication in pediatric oncology that impairs quality of life, nutrition, hydration, and treatment adherence. This randomized, prospective, single blind trial in Mexico will evaluate photobiomodulation (PBM) versus a conventional bioadhesive gel for prevention and treatment of antineoplastic therapy-induced OM in children aged 4-17 with leukemia, lymphoma, or head and neck tumors. A total of 49 participants will be enrolled. The study has two components: (1) Treatment - parallel comparison of PBM versus bioadhesive gel for established OM; (2) Prevention - crossover design in which patients receive both interventions across successive chemotherapy cycles. PBM will be delivered with a 660 nm device, 40 mW, 10 J/cm². The primary outcome is OM grade by the WHO scale assessed on days 7, 11, 14, and 21. Expected results include reduced OM incidence, severity, duration, and pain with favorable safety and tolerability, supporting standardized PBM protocols in pediatric oncology in Mexico.
Eligibility criteria
Qualifiers
Age 4 to 17 years
Histopathologic diagnosis of malignant neoplasm: leukemia, lymphoma, or solid tumor of the head and neck.
Within days 1-3 of the start of any chemotherapy cycle; for leukemia patients, in consolidation phase as defined by protocol.
No signs of oral mucositis at enrollment.
Disqualifiers
Documented primary immunodeficiency.
Severe concomitant systemic infection or unstable medical condition.
PBM treatment within 14 days prior to enrollment.
Known photosensitivity or prior adverse reaction to light therapy.
Trial design
Treatments tested in this trial
- Photobiomodulation
- bioadhesive gel
Treatment groups
Locations
Sponsors and collaborators
Universidad de Guanajuato
Lead sponsor